EMERGING PHARMACOLOGICAL TARGETS IN DIABETIC KIDNEY DISEASE: FROM MOLECULAR MECHANISMS TO PRECISION THERAPEUTICS

Diabetic kidney disease (DKD) is a major microvascular complication of diabetes and an important cause of chronic kidney disease and kidney failure. Although renin–angiotensin system blockade, sodium–glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and non-steroidal mineralocorticoid receptor antagonists have substantially changed the therapeutic landscape, residual risk of kidney disease progression remains. Increasing understanding of glomerular hyperfiltration, podocyte injury, oxidative stress, mitochondrial dysfunction, inflammation and fibrosis has identified new pharmacological opportunities. This review summarizes established pharmacological approaches and emerging molecular targets in DKD, with emphasis on mechanisms, clinical evidence, combination strategies and future precision therapeutics. Clinical evidence from DAPA-CKD, EMPA-KIDNEY, FLOW and FIDELITY demonstrates clinically meaningful renal protection with SGLT2 inhibition, semaglutide and finerenone. Emerging approaches include endothelin-A receptor blockade, aldosterone-synthesis inhibition, anti-inflammatory and anti-fibrotic strategies. Recent combination evidence also suggests that complementary mechanisms may provide greater reduction in albuminuria than monotherapy. DKD pharmacotherapy is therefore transitioning from a predominantly glucose-centered approach toward multi-pathway and potentially precision-based renal protection. Keywords: Diabetic kidney disease; Pharmacology; SGLT2 inhibitors; GLP-1 receptor agonists; Finerenone; Endothelin; NLRP3 inflammasome; Precision medicine.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-20
DOI
https://doi.org/10.5281/zenodo.24387299
Primary Topic
Chronic Kidney Disease and Diabetes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

EMERGING PHARMACOLOGICAL TARGETS IN DIABETIC KIDNEY DISEASE: FROM MOLECULAR MECHANISMS TO PRECISION THERAPEUTICS

Ch.Gopala Krishna, N. Mounika, B. Srinivasa Mani Shankar Reddy, N. Sri Varshitha
2 links
Zenodo (CERN European Organization for Nuclear Research)
Chronic Kidney Disease and Diabetes
article

EMERGING PHARMACOLOGICAL TARGETS IN DIABETIC KIDNEY DISEASE: FROM MOLECULAR MECHANISMS TO PRECISION THERAPEUTICS

Ch.Gopala Krishna, N. Mounika, B. Srinivasa Mani Shankar Reddy, N. Sri Varshitha
article en

Abstract

Diabetic kidney disease (DKD) is a major microvascular complication of diabetes and an important cause of chronic kidney disease and kidney failure. Although renin–angiotensin system blockade, sodium–glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and non-steroidal mineralocorticoid receptor antagonists have substantially changed the therapeutic landscape, residual risk of kidney disease progression remains. Increasing understanding of glomerular hyperfiltration, podocyte injury, oxidative stress, mitochondrial dysfunction, inflammation and fibrosis has identified new pharmacological opportunities. This review summarizes established pharmacological approaches and emerging molecular targets in DKD, with emphasis on mechanisms, clinical evidence, combination strategies and future precision therapeutics. Clinical evidence from DAPA-CKD, EMPA-KIDNEY, FLOW and FIDELITY demonstrates clinically meaningful renal protection with SGLT2 inhibition, semaglutide and finerenone. Emerging approaches include endothelin-A receptor blockade, aldosterone-synthesis inhibition, anti-inflammatory and anti-fibrotic strategies. Recent combination evidence also suggests that complementary mechanisms may provide greater reduction in albuminuria than monotherapy. DKD pharmacotherapy is therefore transitioning from a predominantly glucose-centered approach toward multi-pathway and potentially precision-based renal protection. Keywords: Diabetic kidney disease; Pharmacology; SGLT2 inhibitors; GLP-1 receptor agonists; Finerenone; Endothelin; NLRP3 inflammasome; Precision medicine.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Chronic Kidney Disease and Diabetes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon